Multicenter clinical experience with an atrial lead designed to minimize far-field R-wave sensing

Area of Science:

• Cardiology
• Biomedical Engineering
• Medical Devices

Background:

• Atrial pacing leads can be susceptible to sensing far-field ventricular signals.
• Far-field sensing can lead to inappropriate device behavior, such as mode switching.
• Reducing far-field sensing is crucial for optimizing pacemaker function.

Purpose of the Study:

• To evaluate a novel OptiSense atrial lead designed to minimize far-field ventricular sensing.
• To compare the performance of the OptiSense lead against conventional pacing leads.

Main Methods:

• A randomized trial involving 63 patients with standard pacing indications.
• Patients received either the OptiSense lead or a conventional lead in the right atrium.
• Electrical parameters, far-field sensing thresholds, and inappropriate mode switches were assessed at 90 and 360 days.

Main Results:

• No far-field sensing was detected with the OptiSense lead at 0.3 mV sensitivity, unlike the control group (20-30%).
• Inappropriate mode switching occurred in 4% of the OptiSense group versus 23% in the control group.
• Intracardiac electrogram Holter monitoring revealed no far-field events in the OptiSense group, compared to over 83,000 in 22% of controls.

Conclusions:

• The OptiSense atrial lead significantly reduces ventricular far-field sensing.
• This reduction leads to a decrease in inappropriate mode switching events.
• The OptiSense lead offers satisfactory pacing and sensing performance.